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In silico improvement of β3-peptide inhibitors of p53•hDM2 and
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Abstract
There is great interest in molecules capable of inhibiting the interactions between p53 and its negative
regulators hDM2 and hDMX, as these molecules have validated potential against cancers in which
one or both oncoproteins are overexpressed. We reported previously that appropriately substituted
β3-peptides inhibit these interactions and, more recently, that minimally cationic β3-peptides are
sufficiently cell permeable to upregulate p53-dependent genes in live cells. These observations,
coupled with the known stability of β-peptides in a cellular environment, and the recently reported
structures of hDM2 and hDMX, motivated us to exploit computational modeling to identify β-
peptides with improved potency and/or selectivity. This exercise successfully identified a new β3-
peptide, β53-16, that possesses the highly desirable attribute of high affinity for both hDM2 as well
as hDMX and identifies the 3,4-dichlorophenyl moiety as a novel determinant of hDMX affinity.
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There is great interest in molecules that inhibit interactions between p53 and its negative
regulators hDM2 and hDMX, as these molecules have validated potential against cancers that
overexpress one or both of these oncoproteins.1,2 We reported that substituted β3-peptides can
inhibit these interactions3,4 and, more recently, that minimally cationic β3-peptides are
sufficiently cell permeable to upregulate p53-dependent genes in live cells.5,6 These
observations, coupled with the established intracellular stability of β-peptides7–9 and the
recently reported structures of hDM210 and hDMX,11 motivated us to exploit computational
methods to identify β-peptides with improved potency and/or selectivity. This exercise
successfully identified a new β3-peptide, β53-16, that possesses the desirable attribute of high
affinity for hDM2 and hDMX and identifies the 3,4-dichlorophenyl moiety as a novel
determinant of hDMX affinity.
Our computational modeling began with the application of Visual Molecular Dynamics (VMD)
12 to generate a model of previously reported β53-8 bound to the p53 binding site on hDM2
(Figure 1A). In this model, β53-8 is bound as a 14-helix that is slightly unwound at the C-
terminus, mimicking its conformation in solution.13 The three hDM2 hydrophobic pockets
occupied in the native structure by the p53 side chains of Leu26, Trp23 and Phe19 10 are occupied
in the modeled complex by the corresponding β3-amino acid side chains at positions 3, 6, and
9. An analogous model of β53-8 bound to hDMX was also prepared (Figure 1B).11
We then applied a hierarchical computational strategy to search for alternative side chains that
would improve packing at one or both interfaces. With the de novo design program
BOMB14 we screened over ten thousand β53-8 analogs containing substituted aromatic and
non-aromatic heterocycles and short hydrocarbon side chains in place of Leu26, Trp23 and
Phe19.10 About 50 candidates were identified by scoring and visualization for evaluation with
MCPRO.15 Binding free energies were predicted via Monte Carlo Free Energy Perturbation
(MC/FEP) calculations using the OPLS-AA force field16 for the protein-ligand complex and
the TIP4P model for water.17 In these simulations, the protein backbones remained fixed; the
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affinities of the eight most interesting and synthetically accessible compounds (Figure 1C)
were subsequently reevaluated in a second round of MC/FEP calculations that permitted
backbone motions.18
The models were first validated by evaluating whether they would predict the large increase
in hDM2 affinity realized when the tryptophan side chain at position 6 is replaced by 6-
chlorotryptophan (6-ClW) (compare β53-8 and β53-13,Figure 1C).19 The calculations predict
that substitution of 6-ClW at position 6 should significantly improve binding to hDM2 (ΔΔG
= –2.1 kcal•mol−1) but not hDMX (ΔΔG = +1.0 kcal•mol−1,Figure 2C). These predictions are
fully aligned with the experimental results: the stability of the hDM2•β53-13 complex is
significantly higher (Kd = 30.1 nM, ΔG = –10.25 kcal•mol−1) than that of the hDM2•β53-8
complex (Kd = 204 nM, ΔG = –9.12 kcal•mol−1), whereas the stabilities of the analogous
hDMX complexes are comparable (Kd = 1.6 and 2.1 µM for β53-13 and β53-8, respectively).
The improvement in hDM2 but not hDMX affinity upon substitution of 6-ClW is consistent
with results observed in the context of previously reported ligands.20–23
The models were further validated by their ability to predict the large increase in hDM2 and
hDMX affinity observed for β-peptides containing a central meta-trifluoromethyl phenyl
substituent (CF3F) when compared with an unsubstituted phenyl ring (compare β53-12 with
β53-14,Figure 1C). The calculations predict that the CF3F side chain should favor binding to
both hDM2 and hDMX (ΔΔG = –4.8 and –4.6 kcal•mol−1, respectively). This increase was
also realized experimentally, albeit in an attenuated way: the stability of the hDM2•β53-12
complex is significantly higher (Kd = 28.2 nM, ΔG = –10.29 kcal•mol−1) than that of the
hDM2•β53-14 complex (Kd = 816 nM, ΔG = –8.3 kcal•mol−1); analogous differences are seen
for the hDMX complexes (Figure 2).24
Next we examined whether the affinity of β53-12 could be increased further by substituting
the leucine side chain at position 6 with one of eight cyclic and acyclic hydrocarbon
alternatives. Although few promising candidates emerged from the BOMB and MC/FEP
analyses, we did investigate β53-17, in which the Leu side chain is replaced by Ile. This
substitution was predicted to slightly favor the binding of both hDM2 and hMDX (ΔΔGbind =
–0.9 and –0.3 kcal•mol−1, respectively). However, no increase in affinity was observed, and
these molecules were not studied further. We note that 53-17 is significantly less 14-helical
than 53-12 as judged by circular dichroism analysis (Figure SI-1). As the computational model
does not account for changes in β-peptide secondary structure, it is possible that the observed
change in secondary structure accounts for the poor agreement between prediction and
experiment in this case. The predictions may be also be affected by uncertainty in the structures
of unliganded hDM2 and hDMX as the 23 N-terminal residues of both proteins are only
partially resolved due to their flexibility.25,26
Based on these observations, we returned attention to the central side chain of the hDM2/hDMX
epitope and evaluated the relative hDM2 and hDMX affinities of hundreds of β53-12 analogs
containing substituted phenylalanine analogs at position 6. This analysis suggested that β-
peptides containing either meta-chlorophenylalanine or para-chlorophenylalanine at this
position would show improved affinity for both hDM2 and hDMX when compared with
β53-14 (−3.5 kcal•mol−1 > ΔΔGbind > −2.5 kcal•mol−1). Indeed, the stability of the
hDM2•β53-15 complex (meta-chloro substituent,Figure 1C) is significantly higher (Kd = 150
nM, ΔG = −9.3 kcal•mol−1) than that of hDM2·β53-14; analogous differences are observed
for the hDMX complexes (Figure 2). However, as predicted, the stabilities of the β53-15
complexes were not greater than those of the β53-12 complexes. Therefore, since the gains in
affinity for the para-chlorophenylalanine were predicted to be similar to those of 53-15, this
additional analog was not tested experimentally.
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Finally we examined the effect of a meta,para-dichlorophenylalanine side chain at the central
position of the recognition epitope (β53-16,Figure 1), whose inclusion was predicted to
significantly improve affinity for both hDM2 and hDMX compared to β53-14 (ΔΔGbind = −4.4
and −5.4 kcal•mol−1, respectively. Indeed, the stabilities of both hDM2•β53-16 and
hDMX•β53-16 are significantly higher than the corresponding β53-14 complexes (Kd = 27.6
nM and 155 nM, respectively for β53-16,Figure 2). They also equal or exceed the stabilities
of the corresponding complexes with 53-12. Competition fluorescence polarization
experiments confirm that β53-16 competes with p53AD for binding to hDM2 and hDMX and
shows improved inhibitory potency towards hDMX (Figure SI-2).
Thus, β53-16 offers significantly improved affinity for hDMX without loss of affinity for
hDM2. Analysis of the MC/FEP simulations suggests more favorable interaction of the
dichlorophenyl group with residues 50–54 in hDMX than with equivalent residues 54–58 in
hDM2. We subsequently examined whether the affinity of β53-16 could be improved further
upon replacement of the adjacent phenylalanine side chain with one of twelve substituted
analogs. This scan failed to identify promising substitutions as the phenylalanine side chain
appears to bind tightly to the hydrophobic pocket of both proteins; however minor gains in
affinity for both hDM2 and hDMX were predicted for a para-fluorophenylalanine substitution
(ΔΔGbind = −0.4 and −0.9 kcal•mol−1, respectively). No increase in affinity was observed
experimentally with this peptide, β53-18, so further modification at this position was not
pursued (Figure 1, Table 1). β53-16 represents the highest affinity β3-peptide for hDMX
reported to date, with significantly higher affinity than the prototypic hDM2 ligand, Nutlin-3.
Thus, β53-16 embodies the pan-specificity of well known peptidic hDM2/hDMX
inhibitors27,28 without the limitations of protease sensitivity or poor uptake.
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Figure 1.
Computationally generated models of β53-8 (blue) in complex with (a) hDM2 and (b) hDMX
illustrating differences in binding site topologies. (c) Helical net representations of β3-peptides
studied herein.
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Figure 2.
Direct fluorescence polarization analysis of the affinity of each β-peptide shown for (A) hDM2
and (B) hDMX. (C) Comparison of calculated and experimental binding free energies
expressed in terms of ΔΔGbind relative to the standard shown (kcal•mol−1); Kd values in nM
units.
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